Neuroscience & CNS
Part of Biotech - Drug Development
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 BIIB | Biogen Inc. Common Stock | $28.9b | $195.33 | -0.6% | 880.4K |
 NBIX | Neurocrine Biosciences Inc | $15.9b | $163.85 | -2.1% | 1.1M |
 JAZZ | Jazz Pharmaceuticals, Inc. | $14.8b | $238.47 | -0.7% | 678.0K |
 AXSM | Axsome Therapeutics, Inc | $12.1b | $232.36 | +0.4% | 1.1M |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $11.8b | $20.13 | -9.2% | 101.9K |
 CYTK | Cytokinetics Inc. | $10.4b | $71.44 | -1.2% | 1.6M |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $9.8b | $253.97 | -4.1% | 617.7K |
 ALKS | Alkermes Inc. plc | $7.0b | $42.79 | -1.4% | 1.3M |
 PTCT | PTC Therapeutics, Inc. | $6.1b | $70.94 | +0.4% | 937.1K |
 TGTX | TG Therapeutics, Inc. | $5.8b | $40.13 | -1.1% | 1.8M |
 XENE | Xenon Pharmaceuticals Inc | $5.3b | $51.73 | -2.4% | 1.7M |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.3b | $37.63 | +0.5% | 1.6M |
 ACAD | Acadia Pharmaceuticals Inc. | $3.7b | $21.57 | -0.7% | 807.3K |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.3b | $19.50 | -3.1% | 2.2M |
 ALMS | Alumis Inc. Common Stock | $2.8b | $19.06 | -6.5% | 1.4M |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.7b | $44.74 | +0.1% | 574.1K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $2.6b | $23.55 | -4.2% | 4.2M |
 STOK | Stoke Therapeutics, Inc. Common Stock | $1.9b | $30.04 | -0.3% | 569.5K |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $1.9b | $36.06 | -3.8% | 181.3K |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $1.8b | $32.19 | -2.3% | 462.3K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.7b | $5.50 | -6.6% | 1.4M |
 ATAI | AtaiBeckley Inc. Common Stock | $1.7b | $3.94 | -12.3% | 9.2M |
 BHVN | Biohaven Ltd. | $1.7b | $10.86 | -4.7% | 2.0M |
 GHRS | GH Research PLC Ordinary Shares | $1.6b | $21.43 | -7.8% | 352.0K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $1.6b | $13.30 | -7.1% | 1.7M |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $1.3b | $28.05 | -6.8% | 478.2K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.1b | $33.34 | +2.0% | 333.4K |
 ANNX | Annexon, Inc. Common Stock | $0.9b | $5.28 | -3.1% | 1.8M |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.9b | $68.58 | -8.0% | 712.3K |
 TBPH | Theravance Biopharma, Inc. | $0.8b | $16.30 | -0.4% | 242.8K |
 LBRX | LB Pharmaceuticals Inc Common Stock | $0.8b | $28.46 | -1.5% | 156.8K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.8b | $5.95 | -5.7% | 1.3M |
 ANRO | Alto Neuroscience Inc. | $0.7b | $18.26 | -8.8% | 414.1K |
 PRTA | Prothena Corporation plc Ordinary Shares | $0.5b | $8.77 | -5.2% | 656.3K |
 OVID | Ovid Therapeutics Inc. Common Stock | $0.5b | $2.38 | -4.0% | 1.4M |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $0.5b | $11.48 | -7.0% | 285.4K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $0.5b | $3.92 | -5.2% | 1.2M |
 VNDA | Vanda Pharmaceuticals Inc. | $387.9m | $6.02 | -3.7% | 714.4K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $342.8m | $1.62 | -7.4% | 864.6K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $294.1m | $3.40 | -5.4% | 757.8K |
 AVXL | Anavex Life Sciences | $280.8m | $2.57 | -8.9% | 942.4K |
 ACIU | AC Immune SA | $270.7m | $2.24 | -6.7% | 328.1K |
 ALEC | Alector, Inc. Common Stock | $239.8m | $1.64 | -9.7% | 364.4K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $233.8m | $3.33 | -8.2% | 650.9K |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $231.1m | $1.62 | -2.4% | 627.3K |
 NERV | Minerva Neurosciences, Inc | $228.8m | $4.97 | +4.0% | 114.1K |
 HELP | Cybin Inc. Common Stock | $227.0m | $4.14 | -6.4% | 829.9K |
 NGEN | NervGen Pharma Corp. Common stock | $219.8m | $1.87 | -7.0% | 1.1M |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $196.6m | $11.05 | -7.0% | 481.1K |
 ABOS | Acumen Pharmaceuticals, Inc. Common Stock | $187.8m | $2.14 | -6.5% | 319.6K |